全文获取类型
收费全文 | 27954篇 |
免费 | 2375篇 |
国内免费 | 1610篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 403篇 |
妇产科学 | 104篇 |
基础医学 | 3450篇 |
口腔科学 | 99篇 |
临床医学 | 2465篇 |
内科学 | 12370篇 |
皮肤病学 | 138篇 |
神经病学 | 220篇 |
特种医学 | 510篇 |
外国民族医学 | 4篇 |
外科学 | 933篇 |
综合类 | 5361篇 |
预防医学 | 1914篇 |
眼科学 | 18篇 |
药学 | 2267篇 |
10篇 | |
中国医学 | 1195篇 |
肿瘤学 | 444篇 |
出版年
2024年 | 9篇 |
2023年 | 347篇 |
2022年 | 406篇 |
2021年 | 708篇 |
2020年 | 853篇 |
2019年 | 926篇 |
2018年 | 806篇 |
2017年 | 942篇 |
2016年 | 1054篇 |
2015年 | 1111篇 |
2014年 | 1820篇 |
2013年 | 1907篇 |
2012年 | 1703篇 |
2011年 | 2023篇 |
2010年 | 1492篇 |
2009年 | 1347篇 |
2008年 | 1399篇 |
2007年 | 1520篇 |
2006年 | 1472篇 |
2005年 | 1191篇 |
2004年 | 1036篇 |
2003年 | 919篇 |
2002年 | 837篇 |
2001年 | 848篇 |
2000年 | 706篇 |
1999年 | 538篇 |
1998年 | 450篇 |
1997年 | 419篇 |
1996年 | 389篇 |
1995年 | 422篇 |
1994年 | 358篇 |
1993年 | 305篇 |
1992年 | 283篇 |
1991年 | 205篇 |
1990年 | 168篇 |
1989年 | 140篇 |
1988年 | 154篇 |
1987年 | 130篇 |
1986年 | 89篇 |
1985年 | 98篇 |
1984年 | 82篇 |
1983年 | 54篇 |
1982年 | 55篇 |
1981年 | 52篇 |
1980年 | 46篇 |
1979年 | 29篇 |
1978年 | 38篇 |
1977年 | 23篇 |
1975年 | 6篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
目的了解何首乌致药物性肝损伤(Polygonum multiflorum-associated drug induce liver injury,PM-DILI)的临床病理学特点。方法收集2019年3月1日至2021年3月1日深圳市第三人民医院收治的8例PM-DILI患者临床资料。肝穿组织进行苏木素-伊红染色、网状纤维染色、Masson三色染色、铁、铜特殊染色和免疫组织化学染色,显微镜下观察分析。结果8例PM-DILI患者男女比为1∶1,平均年龄43岁,其中6例为急性PM-DILI,2例慢性为PM-DILI。入院血清学检查异常主要包括转氨酶升高和淤胆均为7例。主要组织病理学改变为点灶状坏死8例、界面炎5例、融合坏死4例,融合坏死以肝腺泡3带为主,不伴或伴少数炎细胞浸润;胆汁淤积5例,为肝腺泡3带的肝细胞、毛细胆管内淤胆,不伴或伴少数炎细胞浸润;中央静脉炎3例;病程长者可发生肝纤维化,甚至肝硬化2例。结论肝腺泡3带为主的急性淤胆和肝细胞坏死是PM-DILI主要组织学表现,严重者可发生静脉炎等血管损伤。 相似文献
2.
Norio Itokawa Masanori Atsukawa Akihito Tsubota Noritomo Shimada Hidenori Toyoda Koichi Takaguchi Atsushi Hiraoka Tomonori Senoh Mai Koeda Yuji Yoshida Tomomi Okubo Taeang Arai Korenobu Hayama Ai Nakagawa-Iwashita Chisa Kondo Katsuhiko Iwakiri 《Internal medicine (Tokyo, Japan)》2021,60(4):507
Objective Pegylated-interferon monotherapy is the standard treatment for patients with chronic hepatitis B; however, the factors associated with its therapeutic effects remain unclear. Methods Patients with chronic hepatitis B were treated with pegylated interferon α-2a for 48 weeks. We evaluated the kinetics of hepatitis B surface antigen (HBsAg) during treatment and follow-up periods and the factors associated with an HBsAg response (defined as a change in HBsAg of ≥-1 log IU/mL from baseline). Results The study population comprised 50 patients. The median baseline levels of hepatitis B virus DNA and HBsAg were 5.00 and 3.40 log IU/mL. The median values of HBsAg reduction from baseline were -0.44 (n=48), -0.41 (n=40), and -0.68 (n=11) log IU/mL at the end of treatment and at 48 and 144 weeks post-treatment, respectively. The rates of HBsAg response were 24.0% and 22.5% at the end of treatment and at 48 weeks post-treatment, respectively. A multivariate analysis identified HBsAg <3.00 log IU/mL as an independent baseline factor contributing to the HBsAg response at the end of treatment and 48 weeks post-treatment (p=1.07×10-2 and 4.42×10-2, respectively). There were significant differences in the reduction of the HBsAg levels at 12 weeks of treatment and in the incidence of serum ALT increase during treatment between patients with and without an HBsAg response. Conclusion These findings suggest that the baseline HBsAg level, HBsAg kinetics at 12 weeks of treatment, and ALT increase during treatment are important factors contributing to the HBsAg response in pegylated interferon α-2a monotherapy for patients with chronic hepatitis B. 相似文献
3.
《Journal of infection and chemotherapy》2022,28(1):95-98
A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes. 相似文献
4.
Won Sohn Yoosoo Chang Yong Kyun Cho Yun Soo Hong Hocheol Shin Seungho Ryu 《Journal of viral hepatitis》2022,29(1):69-77
The predictive role of noninvasive liver fibrosis scores on liver-related mortality in patients with chronic hepatitis B below 40 years of age remains unclarified. We examined the association of liver fibrosis scores with liver-related mortality in young (<40 years) and older adults with hepatitis B virus (HBV) infection. A cohort study was performed in 21,360 HBsAg-positive Korean adults without liver cirrhosis or liver cancer at baseline who were followed up for up to 18 years. The liver fibrosis scores were determined using the fibrosis-4 score (FIB-4) and aspartate transaminase to platelet ratio index (APRI). Patients’ vital status and cause of death were ascertained through the National Death Records. During a median follow-up of 10.2 years, 283 liver-related deaths were identified (liver-related mortality, 127.4/105 person-years). The liver fibrosis scores were significantly associated with increased risks of liver-related mortality; this association did not differ by age group (<40 vs. ≥40 years). The multivariable-adjusted hazard ratios with 95% confidence intervals for liver-related mortality comparing intermediate and high to low FIB-4 scores were 4.23 (1.99–9.00), and 15.16 (5.18–44.38), respectively, among individuals under 40, and 4.46 (3.03–6.56) and 22.47 (15.11–33.41), respectively, among older individuals. These associations were similar in analyses using APRI. In this cohort of HBsAg-positive individuals, the liver fibrosis scores were associated with increased risks of liver-related mortality in young and older adults. The liver fibrosis scores have a role in predicting liver mortality, even in young adults with HBV. 相似文献
5.
目的探讨基础疾病对药物性肝损伤(drug-induced liver injury,DILI)患者严重程度及预后的影响。方法纳入北京友谊医院肝病中心2016年1月至2019年12月符合入排标准的DILI患者,依据查尔森合并症指数(Charlson Comorbidity Index,CCI)分为显著基础疾病负担组(CCI>2分)和无或轻度基础疾病负担组(CCI≤2分),通过卡方检验及非参数检验分析两组患者临床特征、损伤程度及预后。结果313例DILI患者年龄为(54±14)岁,女性227例(72.5%),其中无或轻度基础疾病负担的患者272例(86.9%),显著基础疾病负担的患者41例(13.1%)。与无或轻度基础疾病负担组相比,显著基础疾病负担组年龄更大[(63±8)岁比(52±14)岁]、体质指数[(24.2±5.2)比(23.1±3.6)kg/m2]及谷氨酰转肽酶[初始值283.0(159.0,404.0)U/L比189.0(100.0,325.0)U/L;峰值335.0(239.0,582.0)U/L比219.0(131.0,360.0)U/L]更高,差异均有统计学意义(均P<0.01);严重程度及临床分型两组相比差异无统计学意义(P>0.05)。在本队列中,250例(79.9%)DILI患者恢复正常,41例(13.1%)发展为慢性DILI,22例(7.0%)需要肝移植或者死亡,显著基础疾病负担组全因病死率及非肝脏相关的病死率均显著高于无或轻度基础病负担组患者(19.5%比3.7%;12.2%比0.7%,均P<0.01)。结论基础疾病负担重的患者预后差,以非肝脏相关死亡为主。 相似文献
6.
《Vaccine》2022,40(33):4889-4896
BackgroundDuring the COVID-19 pandemic, the number of hepatitis B virus (HBV) vaccinations among men who have sex with men (MSM) has been considerably lower than before the pandemic. Moreover, less frequent HBV testing and a reduction in numbers of sex partners have been reported. We assessed the impact of these COVID-19-related changes on HBV transmission among MSM in the Netherlands.MethodsWe estimated the changes in sexual activity, HBV testing, and HBV vaccination among MSM during the pandemic from Dutch data. We used a deterministic compartmental model and investigated scenarios with small or large declines in sexual activity, testing, and vaccination for the current phase of the pandemic (without available data). We examined the increase in HBV vaccinations needed to prevent further increase in HBV incidence.ResultsWith a decrease in numbers of sex partners of 15–25% during the first lockdown and 5% during the second lockdown, we found a decline of 6.6% in HBV incidence in 2020, despite a >70% reduction in HBV testing and vaccination during the first lockdown. With numbers of sex partners rebounding close to pre-pandemic level in 2021, and a reduction of 15% in testing and 30% in vaccination in 2021, we found an increase of 1.4% in incidence in 2021 and 3.1% in 2026. With these changes, an increase of ≥60% in HBV vaccinations in 2022 would be needed to bring the HBV incidence in 2023 back to the level that it would have had if the COVID-19-related changes had not occurred.ConclusionsDespite reductions in sexual activity during the COVID-19 pandemic, the decrease in HBV vaccinations may result in a small increase in HBV incidence after 2021, which may persist for years. It is important to restore the vaccination level and limit further increase in HBV transmission among MSM. 相似文献
7.
8.
9.
Jose F. Camargo Shweta Anjan Nafeesa Chin‐Beckford Michele I. Morris Lilian M. Abbo Jacques Simkins Gaetano Ciancio Linda J. Chen George W. Burke Jose Figueiro Giselle Guerra Warren L. Kupin Adela Mattiazzi Mariella Ortigosa‐Goggins Kalyan Ram Bhamidimarri David Roth 《Clinical transplantation》2019,33(5)
10.
《Vaccine》2019,37(35):5059-5066
Background: Hepatitis B virus (HBV) infection is highly endemic in most low income countries including Cambodia. This nationwide serosurvey was conducted to assess the impact of hepatitis B vaccination and to determine whether Cambodia met the WHO regional 2017 target of hepatitis B surface antigen (HBsAg) seroprevalence less than 1% in five-year-old children.Methods: A cross-sectional multi-stage cluster survey was conducted among children born during 2010–2012 and their mothers in Cambodia. HBsAg prevalence was estimated by rapid point-of-care testing, and demographic data, including vaccination history, was collected. Vaccine coverage in children and the prevalence of HBsAg among children and mothers was calculated taking into account the complex survey design. Factors associated with children’s failure to receive timely (within 24 h) vaccination were analysed by multivariate logistic analysis.Findings: A total of 2,520 children 5–7 years old and 2,028 mothers were recruited. In total, 78.4% of children received hepatitis B vaccination birth-dose (HepB-BD); of these, 58.7% were administered ≤ 24 h. Birth at home or “other” location were independent risk factors for children’s failure to receive timely HepB-BD. Overall HBsAg seroprevalence was 4.39% (95%CI: 3.53%–5.45%) among mothers and 0.56% (95%CI: 0.32%–0.98%) among children. The prevalence among children without hepatitis B vaccination was 4.62% (95%CI: 1.31%–14.97%). Among children with a HBsAg-positive mother, prevalence was 10.11% (95%CI: 5.41%–18.11%).Interpretation: Having achieved the 2017 target of less than 1% HBsAg prevalence among 5 years old children, Cambodia can now focus on eliminating mother-to-child transmission of HBV. Moreover, the high HBsAg prevalence among mothers suggests that routine screening with proper linkage to care and treatment is needed. Strengthening measures to improve vaccination coverage further and eliminate mother-to-child transmission by coordinated programming with other services offering additional HBV interventions will help move towards the global goal of hepatitis B elimination by 2030.Funding: As per sources of funding. 相似文献